Key result
Sarcomere mutation-negative HCM is linked to ~74% lower rates of family history than mutation-positive disease.
Why the study?
Many patients with hypertrophic cardiomyopathy lack sarcomere gene mutations, and why these individuals develop asymmetric myocardial hypertrophy remains largely unknown.
Observational (n=127)
No
Sarcomere mutation negative hypertrophic cardiomyopathy is associated with older age at diagnosis, obesity, and higher rates of LVOT obstruction, suggesting non-genetic risk factors may contribute to asymmetric myocardial hypertrophy in these patients.
Distinguishes sarcomere-negative HCM by later onset and lower familial risk; supports hypothesis of alternative drivers but should not yet alter management.
BACKGROUND: Despite advances in our understanding of the genetic causes of hypertrophic cardiomyopathy (HCM), a large portion of this patient population do not carry sarcomere gene mutations when screened. It remains largely unknown why patients without sarcomere mutations develop asymmetric myocardial hypertrophy. METHODS: We performed a retrospective analysis of probands with HCM who underwent genetic testing to determine if clinical phenotypes were different depending on sarcomere mutation status. A medical history, three generation family history and clinical phenotyping were performed on 127 probands with HCM. Genetic screening was performed using clinically available HCM genetic testing panels. RESULTS: We found that probands with HCM with pathogenic sarcomere mutations were over three times more likely to have a family history of HCM (66% vs 17%, p<0.0001) and were diagnosed with HCM at a much younger age (32 vs 51 years old, p<0.0001). In contrast, probands with HCM without sarcomere mutations were significantly more obese (body surface area p=0.003, body mass index p=0.04 adjusted for age) and were more likely to present with left ventricular outflow tract obstruction (p=0.0483). CONCLUSION: Patients with sarcomere mutation negative HCM present at an older age and are more obese compared with patients with sarcomere mutation positive HCM. The role of ageing and obesity in asymmetric myocardial hypertrophy warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Feria et al. (2021) conducted an observational in Hypertrophic cardiomyopathy (n=127). Sarcomere mutation negative status vs. Sarcomere mutation positive status was evaluated on Family history of HCM (p=<0.0001). Patients with sarcomere mutation negative HCM were significantly less likely to have a family history of HCM (17% vs 66%), presented at an older age (51 vs 32 years), and were more obese compared to those with sarcomere mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: